NeurologyLive® Friday 5 — February 7, 2024

Author(s):

Key Takeaways

January 2025 FDA updates include approvals of SPN-830 for Parkinson's and AXS-07 for migraines, marking significant advancements in treatment options.
Julie Flygare highlighted the critical role of social support in enhancing the quality of life for narcolepsy patients.
Sushma Kola emphasized integrative approaches and research developments in neurology care for 2025, reflecting ongoing innovation in the field.
Expert insights from Stuart Isaacson and Stewart Tepper provide valuable perspectives on recent FDA approvals and their implications for patient care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 7, 2024.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, January 2025: Approvals, Clearances, and Designations

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive^®team.

2: Patient Perspective on the Role of Social Support in Managing Narcolepsy: Julie Flygare, JD

The president and CEO at Project Sleep talked about the foundational role of social connections and peer support in improving quality of life for individuals with narcolepsy. [WATCH TIME: 5 minutes]

3: Reaction and Significance of SPN-830 Approval for Parkinson Disease: Stuart Isaacson, MD, FAAN

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, discussed SPN-830, the first and only FDA-approved subcutaneous apomorphine infusion device for patients with Parkinson disease. [WATCH TIME: 2 minutes]

4: NeuroVoices: Sushma Kola, MD, on Integrative Approaches and Research Developments for Neurology Care in 2025

The movement disorder specialist and director of Integrative Neurosciences at Allegheny Health Network discussed key advancements in the field of neurology for 2025.

5: Medical Insights on the Recent Approval of AXS-07 for Acute Migraine Treatment: Stewart Tepper, MD

The professor of neurology at the Geisel School of Medicine at Dartmouth shared his reaction to the recent FDA approval of AXS-07, a combination of meloxicam and rizatriptan, as a new therapy for acute migraine management. [WATCH TIME: 4 minutes]